Utility of BAP1, p16, and Methylthio-Adenosine Phosphorylase Immunohistochemistry in Cytological and Histological Samples of Pleural Mesotheliomas.


Journal

Acta cytologica
ISSN: 1938-2650
Titre abrégé: Acta Cytol
Pays: Switzerland
ID NLM: 0370307

Informations de publication

Date de publication:
2023
Historique:
received: 14 02 2023
accepted: 02 03 2023
medline: 4 8 2023
pubmed: 9 3 2023
entrez: 8 3 2023
Statut: ppublish

Résumé

In most cases, the diagnostic workup of pleural mesotheliomas (MPMs) starts with cytological examination of pleural effusion, but histology is needed to confirm the diagnosis. The introduction of BAP1 and methylthio-adenosine phosphorylase (MTAP) immunohistochemistry has become a powerful tool to confirm the malignant nature of mesothelial proliferations also in cytological specimens. The objective of this study was to determine the concordance of BAP1, MTAP, and p16 expression between cytological and histological samples of patients with MPM. Immunohistochemistry of BAP1, MTAP, and p16 was performed on cytological samples and compared with the corresponding histological specimen of 25 patients with MPM. Inflammatory and stromal cells served as positive internal control for all three markers. In addition, samples of 11 patients with reactive mesothelial proliferations served as an external control group. Loss of BAP1, MTAP, and p16 expression was found in 68%, 72%, and 92% of MPM, respectively. Loss of MTAP was associated with loss of p16 expression in all cases. Concordance of BAP1 between cytological and corresponding histological samples was 100% (kappa coefficient 1; p = 0.008). For MTAP and p16, kappa coefficient was 0.9 (p = 0.01) and 0.8 (p = 0.7788), respectively. Concordant BAP1, MTAP, and p16 expression is found between cytological and corresponding histological samples, indicating that a reliable diagnosis of MPM can be made on cytology only. Of the three markers, BAP1 and MTAP are most reliable in distinguishing malignant from reactive mesothelial proliferations.

Identifiants

pubmed: 36889303
pii: 000530002
doi: 10.1159/000530002
doi:

Substances chimiques

adenosine phosphorylase EC 2.4.2.-
Tumor Suppressor Proteins 0
Biomarkers, Tumor 0
BAP1 protein, human 0
Ubiquitin Thiolesterase EC 3.4.19.12

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

444-450

Informations de copyright

© 2023 The Author(s). Published by S. Karger AG, Basel.

Auteurs

Vera Amacher (V)

Department of Pathology and Molecular Pathology, University Hospital Zürich, Zurich, Switzerland.

Peter Karl Bode (PK)

Institute of Pathology, Cantonal Hospital Winterthur, Winterthur, Switzerland.

Holger Moch (H)

Department of Pathology and Molecular Pathology, University Hospital Zürich, Zurich, Switzerland.

Daniela Lenggenhager (D)

Department of Pathology and Molecular Pathology, University Hospital Zürich, Zurich, Switzerland.

Bart Vrugt (B)

Department of Pathology, Hospital Münsterlingen, Münsterlingen, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH